IL267191A - - Google Patents

Info

Publication number
IL267191A
IL267191A IL26719119A IL26719119A IL267191A IL 267191 A IL267191 A IL 267191A IL 26719119 A IL26719119 A IL 26719119A IL 26719119 A IL26719119 A IL 26719119A IL 267191 A IL267191 A IL 267191A
Authority
IL
Israel
Application number
IL26719119A
Other languages
Hebrew (he)
Other versions
IL267191B2 (en
IL267191B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL267191A publication Critical patent/IL267191A/he
Publication of IL267191B1 publication Critical patent/IL267191B1/en
Publication of IL267191B2 publication Critical patent/IL267191B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL267191A 2016-12-14 2019-06-10 Use of a carbamate compound to prevent, relieve or treat tremors or tremor syndrome IL267191B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14
PCT/KR2017/014743 WO2018111009A1 (ko) 2016-12-14 2017-12-14 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
IL267191A true IL267191A (https=) 2019-07-31
IL267191B1 IL267191B1 (en) 2023-01-01
IL267191B2 IL267191B2 (en) 2023-05-01

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267191A IL267191B2 (en) 2016-12-14 2019-06-10 Use of a carbamate compound to prevent, relieve or treat tremors or tremor syndrome

Country Status (13)

Country Link
US (1) US11033531B2 (https=)
EP (1) EP3556364B1 (https=)
JP (1) JP7086076B2 (https=)
KR (1) KR102635941B1 (https=)
CN (1) CN110267657B (https=)
AU (1) AU2017374459B2 (https=)
CL (1) CL2019001623A1 (https=)
ES (1) ES3039979T3 (https=)
IL (1) IL267191B2 (https=)
MX (1) MX391363B (https=)
MY (1) MY198417A (https=)
WO (1) WO2018111009A1 (https=)
ZA (1) ZA201903749B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3711760B1 (en) * 2017-11-14 2024-02-14 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
US20220117941A1 (en) * 2018-09-21 2022-04-21 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2014142518A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating a movement disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1732564A1 (en) 2004-03-29 2006-12-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
CA2679206C (en) * 2007-03-05 2015-02-24 Indus Biotech Private Limited Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof
PL2445890T3 (pl) 2009-06-22 2016-02-29 Sk Biopharmaceuticals Co Ltd Sposób wytwarzania estru (R)-1-arylo-2-tetrazoliloetylowego kwasu karbaminowego
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2014142518A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating a movement disorder

Also Published As

Publication number Publication date
WO2018111009A1 (ko) 2018-06-21
JP2020502137A (ja) 2020-01-23
MX2019006941A (es) 2019-09-06
CN110267657A (zh) 2019-09-20
RU2019121914A3 (https=) 2021-04-21
IL267191B2 (en) 2023-05-01
IL267191B1 (en) 2023-01-01
CL2019001623A1 (es) 2019-08-23
ES3039979T3 (en) 2025-10-28
CN110267657B (zh) 2022-12-13
BR112019012000A2 (pt) 2019-10-29
MX391363B (es) 2025-03-21
KR20190087573A (ko) 2019-07-24
EP3556364A1 (en) 2019-10-23
RU2019121914A (ru) 2021-01-15
MY198417A (en) 2023-08-29
AU2017374459B2 (en) 2023-04-27
US11033531B2 (en) 2021-06-15
EP3556364B1 (en) 2025-08-27
KR102635941B1 (ko) 2024-02-13
EP3556364A4 (en) 2020-06-17
AU2017374459A1 (en) 2019-07-04
ZA201903749B (en) 2022-01-26
CA3046300A1 (en) 2018-06-21
US20190336481A1 (en) 2019-11-07
JP7086076B2 (ja) 2022-06-17

Similar Documents

Publication Publication Date Title
CH714036A1 (https=)
BR122021017409A2 (https=)
BR112019002665A2 (https=)
BR112019009263A2 (https=)
BR112019009262A2 (https=)
BR112019008087A2 (https=)
BR202017015425U2 (https=)
BR112019009373A2 (https=)
BR202016021748U2 (https=)
BE2016C010I2 (https=)
CN303536736S (https=)
CN303537546S (https=)
CN303536106S (https=)
CN303536127S (https=)
CN303536212S (https=)
CN303536216S (https=)
CN303536221S (https=)
CN303536278S (https=)
CN303536284S (https=)
CN303536357S (https=)
CN303536361S (https=)
CN303536428S (https=)
CN303536593S (https=)
CN303536597S (https=)
CN303662293S (https=)